OUR TECHNOLOGY

Disruptive, proprietary enzymatic DNA vector

We are disrupting the decades-old technology of DNA manufacturing with our GMP-licensed facility, empowering you to advance genetic medicine with confidence.

Innovating DNA for the Future

Traditionally, DNA is manufactured using E.coli fermentation. This method for manufacturing plasmid DNA (pDNA) is inherently limited in terms of speed, safety, cost, capacity, and scalability.

At Touchlight, we are pioneering cell-free DNA synthesis with our proprietary dbDNA™ technology. Our advanced cell-free DNA platform supports a range of applications, including viral vectors, non viral, mRNA, gene editing and vaccine applications, offering safer and more economical alternatives that accelerate the progress of your project.

dbDNA™: High-Performance Enzymatic DNA

dbDNA™ is a covalently closed linear DNA vector that enhances gene therapy performance across viral and non-viral platforms. It reduces DNA input, improves titres and capsid quality, and preserves vital elements like ITRs. In non-viral use, it boosts expression, RNA yield, and tolerability, especially in LNPs, while supporting large-payload genome editing and DNA vaccines. Designed for complex and GC-rich sequences, it offers high purity, safety, and scalability for applications from vaccines to advanced therapeutics.

Key Features of dbDNA™

Faster to Clinic
dbDNA™ is produced rapidly with a streamlined, cell-free process—helping you shorten development timelines and accelerate your path to patients.

Lower DNA Input, Better Cost Efficiency
High-expression performance means less DNA is needed, reducing material use and improving the overall cost profile of your therapeutic.

Clinically Validated Across Modalities
dbDNA™ is already supporting programs across mRNA, AAV, gene editing, and more—demonstrating versatility and clinical acceptance in the field.

HOW IT SUPPORTS YOUR APPLICATION

mbDNA™: Single-Stranded Circular DNA

mbDNA™ is a synthetic single-stranded DNA template with a stem-loop structure and nuclease recognition site, enabling nuclease-guided nuclear delivery after cleavage. It achieves 75% knock-in/knock-out efficiency, 2-fold higher cell viability, and exceptional recovery, especially in primary T cells, outperforming pDNA. Optimised for sequences over 20 kb, mbDNA™ supports HDR, works with any nuclease, and offers unmatched versatility for precise gene editing.

Key Features of mbDNA™

Enhanced precision for gene editing

Improved stability and safety

Scalable for pharmaceutical applications

Next-Generation DNA Innovation: z- dbDNA™

z- dbDNA™ is the optimal template for mRNA production via in vitro transcription (IVT). Our platform enables rapid, scalable development and GMP production without the need for a Master Cell Bank, and a reduced quantity of DNA is required for equivalent IVT yields. In addition, it supports complex sequence production, such as long polyA tails (>120A), and can incorporate genes of interest up to 20kb making it very flexible to support RNA based therapeutics

Key Features of z- dbDNA™

Best in class synthetic DNA

Reduced template usage for improved positively impacting COGs

Excellent RNA integrity

dbDNA™ platform

>5x faster than pDNA manufacture

Our proprietary enzymatic DNA manufacturing platform enables multi-gram DNA production in weeks, rather than the months. Compared to plasmid DNA using traditional E.coli fermentation methods, we believe this method will help streamline and accelerate your workflows, bringing your research to market quickly without compromise.

Rapid manufacturing (5 day GMP process)

Easy scale-up and scale-out

Supports toxic & unstable sequences across all applications

Cost effective at scale, no cell banking & testing, no KanR assays

How our process works

We harness cutting-edge enzymatic DNA technology to streamline production, ensuring efficiency, precision, and scalability for genetic applications. Our proprietary approach eliminates your reliance on bacterial systems, enabling high-purity DNA synthesis at unprecedented speeds.

Template Preparation

The DNA template, containing the sequence of interest, undergoes denaturation, ensuring it is primed for enzymatic amplification.

Enzymatic Amplification

Φ29 DNA Polymerase and primers initiate high-fidelity amplification, generating long, linear, double-stranded concatemers that serve as the foundation for dbDNA™ synthesis.

Cleavage and Circularisation

Protelomerase binds to the linear DNA at specific sites, carrying out a cleavage-joining reaction to transform the amplified DNA into covalently closed dbDNA™ molecules.

Purification and Final Processing

The mixture is partially purified to remove impurities before targeted restriction enzymes, exonucleases, and filtration steps ensure high-purity, backbone-free dbDNA™, ready for clinical and therapeutic applications.

Revolutionising DNA manufacture

Our proprietary enzymatic DNA production process, enables you to rapidly manufacture multiple grams of DNA using benchtop, disposable equipment.

Benefits of our technology in your workflow

Our advanced DNA platform enhances efficiency, scalability, and precision for your genetic applications, providing a robust alternative to traditional plasmid-based methods.